文献速递神经肿瘤

英国全国范围内贝伐珠单抗治疗儿童低级别胶质瘤的安全性、疗效、视觉并发症与结局评估

A nationwide evaluation of bevacizumab-based treatments in pediatric low-grade glioma in the UK: Safety, efficacy, visual morbidity, and outcomes.
PubMed 文献 · Neuro Oncol · 2023-01-01

英国11中心2009-2020年纳入88例儿童低级别胶质瘤(PLGG)接受贝伐珠单抗方案(BBT),85%为三线联合伊立替康、15%联合一线/二线化疗;毒性有限,部分缓解40%、稳定49%、进展11%,但停药后中位8个月65%进展,3年无进展生存率29%;视觉改善29%、稳定49%,3年视觉无进展生存率53%,神经纤维瘤病1型相关视路胶质瘤视觉结局更优。

要点

  • BBT短期控制PLGG有效,部分缓解40%、稳定49%,但停药后中位8个月65%进展,3年无进展生存率29%。
  • 视觉改善29%、稳定49%,3年视觉无进展生存率53%,最佳眼视觉结局优于最差眼。
  • 神经纤维瘤病1型相关视路胶质瘤视觉结局更优(P = .023),视觉与影像学反应一致率36%。

核心结论

  • BBT可有效短期控制PLGG并延迟进一步进展,视觉反应(最佳眼优于最差眼)比影像学反应更持久。
  • 进一步研究可优化BBT作为视路胶质瘤潜在保视策略的作用。

研究设计与样本

  • 英国全国服务评估,纳入11个中心2009-2020年接受贝伐珠单抗方案治疗的儿童低级别胶质瘤患儿88例。
  • 采用标准化神经影像(RANO-LGG)与视觉(logMAR视力)标准评估临床-影像相关性、生存结局及多因素预后分析。

主要发现

  • 88例中85%为三线联合伊立替康,15%联合一线/二线化疗;毒性有限且轻微。
  • BBT期间部分缓解40%、稳定49%、进展11%;停药后中位8个月65%进展,影像学3年无进展生存率29%。
  • 间脑综合征与不良无进展生存相关(P = .03)。
  • 治疗前视觉并发症包括单眼盲25%、双眼盲11%;视力改善29%、稳定49%,多见于最佳眼;BBT期间14例(22%)视力恶化,多见于最差眼,3年视觉无进展生存率53%。
  • 神经纤维瘤病1型相关视路胶质瘤视觉结局更优(P = .023);视觉与影像学反应一致率36%,仅用最佳眼反应优化至48%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bevacizumab is increasingly used in children with pediatric low-grade glioma (PLGG) despite limited evidence. A nationwide UK service evaluation was conducted to provide larger cohort "real life" safety and efficacy data including functional visual outcomes. METHODS: Children receiving bevacizumab-based treatments (BBT) for PLGG (2009-2020) from 11 centers were included. Standardized neuro-radiological (RANO-LGG) and visual (logMAR visual acuity) criteria were used to assess clinical-radiological correlation, survival outcomes and multivariate prognostic analysis. RESULTS: Eighty-eight children with PLGG received BBT either as 3rd line with irinotecan (85%) or alongside 1st/2nd line chemotherapies (15%). Toxicity was limited and minimal. Partial response (PR, 40%), stable disease (SD, 49%), and progressive disease (PD, 11%) were seen during BBT. However, 65% progressed at 8 months (median) from BBT cessation, leading to a radiology-based 3 yr-progression-free survival (PFS) of 29%. Diencephalic syndrome (P = .03) was associated with adverse PFS. Pre-existing visual morbidity included unilateral (25%) or bilateral (11%) blindness. Improvement (29%) or stabilization (49%) of visual acuity was achieved, more often in patients' best eyes. Vision deteriorated during BBT in 14 (22%), with 3-year visual-PFS of 53%; more often in patients' worst eyes. A superior visual outcome (P = .023) was seen in neurofibromatosis type 1-associated optic pathway glioma (OPG). Concordance between visual and radiological responses was 36%; optimized to 48% using only best eye responses. CONCLUSIONS: BBTs provide effective short-term PLGG control and delay further progression, with a better sustained visual (best > worst eye) than radiological response. Further research could optimize the role of BBT toward a potentially sight-saving strategy in OPG.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Green K, Panagopoulou P, D'Arco F, et al. A nationwide evaluation of bevacizumab-based treatments in pediatric low-grade glioma in the UK: Safety, efficacy, visual morbidity, and outcomes. Neuro Oncol. 2023. PMID: 36239316. doi:10.1093/neuonc/noac223

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。